middle.news
Argenica Advances Stroke Trial and Secures FDA Orphan Status for ARG-006
9:23am on Thursday 30th of January, 2025 AEDT
•
Biotechnology
Read Story
Argenica Advances Stroke Trial and Secures FDA Orphan Status for ARG-006
9:23am on Thursday 30th of January, 2025 AEDT
Key Points
80% patient dosing completed in Phase 2 ARG-007 acute ischaemic stroke trial
FDA grants Orphan Drug and Rare Pediatric Disease designations for ARG-006
Positive preclinical data supports ARG-007’s potential in Alzheimer’s and Parkinson’s diseases
Cash reserves stand at $15.06 million after a cashflow positive quarter
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE